Effect of anti-inflammatory drugs on overall risk of comin general practice research database

BMJ: British Medical Journal

320, 1642-1646

DOI: 10.1136/bmj.320.7250.1642

Citation Report

#	Article	IF	CITATIONS
2	Aspirin and NSAIDs protect against common GI cancers?. Inpharma Weekly, 2000, &NA, 11.	0.0	0
3	Risk factors for squamous cell carcinoma of the oesophagus in women: a case–control study. British Journal of Cancer, 2001, 85, 1667-1670.	2.9	74
4	Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement. American Journal of Medicine, 2001, 110, S79-S100.	0.6	18
5	Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncology, The, 2001, 2, 544-551.	5.1	481
6	Inflammation, carcinogenesis and cancer. International Immunopharmacology, 2001, 1, 1651-1667.	1.7	133
7	Inflammation and cancer: back to Virchow?. Lancet, The, 2001, 357, 539-545.	6.3	6,677
8	COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in the treatment of pain in the elderly. Clinics in Geriatric Medicine, 2001, 17, 489-502.	1.0	43
9	GASTROINTESTINAL SAFETY OF COX-2 SPECIFIC INHIBITORS. Gastroenterology Clinics of North America, 2001, 30, 921-936.	1.0	26
10	The prevention of colorectal cancer. Alimentary Pharmacology and Therapeutics, 2001, 15, 323-336.	1.9	25
11	Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis, 2001, 22, 1393-1397.	1.3	109
12	Barrett's-related esophageal adenocarcinoma: is chemoprevention a potential option?. American Journal of Gastroenterology, 2001, 96, 2302-2305.	0.2	32
13	Breast cancer and NSAID use: a meta-analysis. British Journal of Cancer, 2001, 84, 1188-1192.	2.9	228
14	Chronic immune activation and inflammation as the cause of malignancy. British Journal of Cancer, 2001, 85, 473-483.	2.9	459
15	Familiar drugs may prevent cancer. Postgraduate Medical Journal, 2001, 77, 492-497.	0.9	4
16	NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. American Journal of Gastroenterology, 2002, 97, 542-553.	0.2	115
17	Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. American Journal of Gastroenterology, 2002, 97, 1888-1895.	0.2	774
18	Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 267-273.	0.2	11
19	Chronic immune activation and inflammation in the pathogenesis of aids and cancer. Advances in Cancer Research, 2002, 84, 231-276.	1.9	142

#	Article	IF	CITATIONS
20	Association Between Nonsteroidal Anti-Inflammatory Drug Use and the Incidence of Pancreatic Cancer. Journal of the National Cancer Institute, 2002, 94, 1168-1171.	3.0	137
21	COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-Cancer Drugs, 2002, 13, 127-137.	0.7	169
22	Celecoxib, a Cyclooxygenase 2 Inhibitor as a Potential Chemopreventive to UV-Induced Skin Cancer. Archives of Dermatology, 2002, 138, 751.	1.7	92
23	The Role of Eicosanoids, Cyclooxygenases, and Nonsteroidal Anti-inflammatory Drugs in Colorectal Tumorigenesis and Chemoprevention. Journal of Clinical Gastroenterology, 2002, 34, 117-125.	1.1	12
24	Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. Journal of the National Cancer Institute, 2002, 94, 252-266.	3.0	1,300
25	Barrett's-related esophageal cancer: Has the final hurdle been cleared, now paving the way for human chemoprevention trials?. Gastroenterology, 2002, 122, 1172-1175.	0.6	18
26	NSAIDs and Gastrointestinal Cancer Prevention. Drugs, 2002, 62, 945-956.	4.9	45
27	Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding. Expert Opinion on Drug Safety, 2002, 1, 245-252.	1.0	19
28	The diet-induced proinflammatory state:. Journal of Manipulative and Physiological Therapeutics, 2002, 25, 168-179.	0.4	48
29	Tumor necrosis factor or tumor promoting factor?. Cytokine and Growth Factor Reviews, 2002, 13, 135-141.	3.2	469
30	Prevention of tumor spread by matrix metalloproteinase-9 inhibition: old drugs, new concept. European Journal of Internal Medicine, 2002, 13, 101-103.	1.0	16
31	Effect of Nonsteroidal Anti-Inflammatory Agents and Finasteride on Prostate Cancer Risk. Journal of Urology, 2002, 168, 1985-1988.	0.2	58
32	A Population-Based Study of Daily Nonsteroidal Anti-inflammatory Drug Use and Prostate Cancer. Mayo Clinic Proceedings, 2002, 77, 219-225.	1.4	131
33	Regular aspirin use and lung cancer risk. BMC Cancer, 2002, 2, 31.	1.1	81
34	Regular use of aspirin and pancreatic cancer risk. BMC Public Health, 2002, 2, 18.	1.2	51
35	Association Between Acetaminophen or Nonsteroidal Antiinflammatory Drugs and Risk of Developing Ovarian, Breast, or Colon Cancer. Pharmacotherapy, 2002, 22, 303-309.	1.2	88
36	Genetic susceptibility and gastric cancer risk. International Journal of Cancer, 2002, 100, 249-260.	2.3	277
37	Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer, 2002, 94, 950-963.	2.0	57

#	Article	IF	CITATIONS
38	Intestinal metaplasia and gastric carcinogenesis. Alimentary Pharmacology and Therapeutics, 2002, 16, 1209-1216.	1.9	147
39	Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Alimentary Pharmacology and Therapeutics, 2002, 16, 1945-1953.	1.9	150
40	The prevention and treatment of dysplasia in gastroesophageal reflux disease: The results and the challenges ahead. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, S113-S124.	1.4	5
41	Aspirin and lung cancer in women. British Journal of Cancer, 2002, 87, 49-53.	2.9	79
42	Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes and Control, 2002, 13, 427-434.	0.8	95
43	Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes and Control, 2003, 14, 413-418.	0.8	36
44	Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes and Control, 2003, 14, 915-922.	0.8	52
45	Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer, 2003, 3, 28.	1.1	159
46	Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer, 2003, 97, 1732-1736.	2.0	80
47	Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. International Journal of Cancer, 2003, 106, 409-415.	2.3	69
48	Cyclooxygenase-2 and gastric carcinogenesis. Apmis, 2003, 111, 915-925.	0.9	108
50	Prevention of gastric cancer. Chinese Journal of Digestive Diseases, 2003, 4, 100-104.	1.1	1
51	Cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study. Alimentary Pharmacology and Therapeutics, 2003, 17, 379-386.	1.9	26
52	A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. British Journal of Cancer, 2003, 88, 684-688.	2.9	148
53	Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. British Journal of Cancer, 2003, 88, 1687-1692.	2.9	211
54	Cyclooxygenase-2 as a Potential Target in the Prevention and Treatment of Genitourinary Tumors: A Review. Journal of Urology, 2003, 169, 2352-2359.	0.2	79
56	Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology, 2003, 124, 1758-1766.	0.6	42
57	Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial 1 1The authors thank the women and men who participated in the study, P. E. Douziech for coordination of treatments, and the hospital pharmacists for preparation of the treatments in the trial centers Gastroenterology, 2003, 125, 328-336.	0.6	391

#	Article	IF	Citations
58	NO-NSAIDs and cancer: promising novel agents. Digestive and Liver Disease, 2003, 35, S27-S34.	0.4	7
59	Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology, 2003, 124, 47-56.	0.6	480
60	Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. Lung Cancer, 2003, 39, 1-13.	0.9	48
61	COX-2 Inhibitors and Other NSAIDs in Bladder and Prostate Cancer. , 2003, 37, 163-178.		12
62	Expression of COX-2 in Stomach Cancers and Its Relation to Their Biological Features. Digestive Surgery, 2003, 20, 107-114.	0.6	19
63	Cancer and the Cyclo-oxygenase Enzyme. American Journal of Cancer, 2003, 2, 27-55.	0.4	14
64	Aspirin use and lung cancer in men. British Journal of Cancer, 2003, 89, 1705-1708.	2.9	50
65	Effects of an Automated Electronic Reminder in Changing the Antiplatelet Drug-Prescribing Behavior Among Italian General Practitioners in Diabetic Patients: An intervention trial. Diabetes Care, 2003, 26, 1497-1500.	4.3	82
66	Use of NSAIDs for the Chemoprevention of Colorectal Cancer. Annals of Pharmacotherapy, 2003, 37, 1664-1674.	0.9	62
67	Non-steroidal Anti-inflammatory Drug Use and the Risk of Gastric Cancer: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2003, 95, 1784-1791.	3.0	236
68	Development of COX Inhibitors in Cancer Prevention and Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, S48-S57.	0.6	19
69	Epidemiology of Non-Steroidal Anti-Inflammatory Drugs and Cancer. , 2003, 37, 1-24.		148
70	Cyclooxygenase-2: A Target for the Prevention and Treatment of Cancers of the Upper Digestive Tract., 2003, 37, 107-123.		3
71	NSAIDs and Chemoprevention. Current Cancer Drug Targets, 2004, 4, 29-42.	0.8	199
72	Tumor Growth Inhibition by Indomethacin in a Mouse Model of Human Medullary Thyroid Cancer: Implication of Cyclooxygenases and 15-Hydroxyprostaglandin Dehydrogenase. Endocrinology, 2004, 145, 2561-2571.	1.4	42
73	Aspirin Use and Pancreatic Cancer Mortality in a Large United States Cohort. Journal of the National Cancer Institute, 2004, 96, 524-528.	3.0	83
74	A Prospective Study of Aspirin Use and the Risk of Pancreatic Cancer in Women. Journal of the National Cancer Institute, 2004, 96, 22-28.	3.0	133
75	Association of Frequency and Duration of Aspirin Use and Hormone Receptor Status With Breast Cancer Risk. JAMA - Journal of the American Medical Association, 2004, 291, 2433.	3.8	242

#	Article	IF	Citations
76	Cyclooxygenase-2 in Lung Carcinogenesis and Chemoprevention. Chest, 2004, 125, 134S-140S.	0.4	13
77	Pathogenesis of Pre-Neoplastic Lesions of the Stomach: Targets for Prevention. Digestive Diseases, 2004, 22, 306-312.	0.8	5
78	Chemoprevention of Gastric Cancer: Role of COX-2 Inhibitors and Other Agents. Digestive Diseases, 2004, 22, 320-326.	0.8	19
79	Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. British Journal of Cancer, 2004, 90, 93-99.	2.9	159
80	What Now for Aspirin and Cancer Prevention?. Journal of the National Cancer Institute, 2004, 96, 4-5.	3.0	24
81	Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis. Carcinogenesis, 2004, 25, 1853-1858.	1.3	40
82	Cyclooxygenase-2 Expression in Prostate Cancer: An Inconsistent Therapeutic Target. UroOncology, 2004, 4, 113-118.	0.1	0
83	Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Alimentary Pharmacology and Therapeutics, 2004, 20, 645-655.	1.9	23
84	Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage. Alimentary Pharmacology and Therapeutics, 2004, 20, 793-802.	1.9	18
85	New approaches to the role of diet in the prevention of cancers of the alimentary tract. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 551, 9-28.	0.4	142
86	COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Seminars in Oncology, 2004, 31, 36-44.	0.8	51
87	What are the beneficial and adverse effects of aspirin in diabetic patients?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2004, 21, 131-133.	0.2	1
88	Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer, 2004, 101, 133-138.	2.0	94
89	NSAID-Related Psychiatric Adverse Events. Drugs, 2004, 64, 2619-2627.	4.9	53
90	Evidence for colorectal cancer cell specificity of aspirin effects on NFκB signalling and apoptosis. British Journal of Cancer, 2004, 91, 381-388.	2.9	95
91	Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Selective Inhibitors for Prostate Cancer Chemoprevention. Journal of Urology, 2004, 171, S59-62; discussion S62-3.	0.2	75
92	Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Human Pathology, 2004, 35, 488-495.	1.1	80
93	Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro1. Journal of Surgical Research, 2004, 119, 143-148.	0.8	24

#	Article	IF	CITATIONS
94	COX-2: a target for prevention and treatment of esophageal cancer. Journal of Surgical Research, 2004, 117, 114-120.	0.8	26
95	THE ROLE OF INFLAMMATION IN THE PATHOGENESIS OF PROSTATE CANCER. Journal of Urology, 2004, 172, S6-11; discussion S11-2.	0.2	293
96	Association of Frequency and Duration of Aspirin Use and Hormone Receptor Status With Breast Cancer Risk. Obstetrical and Gynecological Survey, 2004, 59, 771-773.	0.2	1
97	Cyclooxygenase-2 and Thromboxane Synthase in Non-Endocrine and Endocrine Tumors: A Review. Endocrine Pathology, 2005, 16, 253-278.	5.2	18
98	Systematic review: the chemoprevention of oesophageal adenocarcinoma. Alimentary Pharmacology and Therapeutics, 2005, 22, 759-768.	1.9	28
100	Cyclooxygenase-2: A Therapeutic Target for Prostate Cancer. Clinical Genitourinary Cancer, 2005, 4, 203-211.	0.9	12
101	Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus. International Journal of Cancer, 2005, 116, 903-908.	2.3	17
102	Use of nonaspirin NSAIDs and risk of lung cancer. International Journal of Cancer, 2005, 117, 873-876.	2.3	13
103	The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiology and Drug Safety, 2005, 14, 443-451.	0.9	289
104	Use of Nonsteroidal Antiinflammatory Drugs and Risk of Breast Cancer: The Case-Control Surveillance Study Revisited. American Journal of Epidemiology, 2005, 162, 165-170.	1.6	77
105	Repression of Â-catenin function in malignant cells by nonsteroidal antiinflammatory drugs. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18567-18571.	3.3	79
106	<i>Helicobacter pylori</i> i>Induced Invasion and Angiogenesis of Gastric Cells Is Mediated by Cyclooxygenase-2 Induction through TLR2/TLR9 and Promoter Regulation. Journal of Immunology, 2005, 175, 8242-8252.	0.4	141
107	Nonsteroidal Anti-Inflammatory Drug Use and Breast Cancer Risk by Stage and Hormone Receptor Status. Journal of the National Cancer Institute, 2005, 97, 805-812.	3.0	123
108	Use of Nonsteroidal Antiinflammatory Drugs and Risk of Colon Cancer in a Population-based, Case-Control Study of African Americans and Whites. American Journal of Epidemiology, 2005, 162, 548-558.	1.6	48
109	A Large Cohort Study of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs and Prostate Cancer Incidence. Journal of the National Cancer Institute, 2005, 97, 975-980.	3.0	171
110	Nonsteroidal Anti-inflammatory Drugs and Risk of Esophageal and Gastric Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 444-450.	1.1	54
111	Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer. JAMA - Journal of the American Medical Association, 2005, 294, 914.	3.8	411
112	Nonsteroidal Antiinflammatory Drug Use and Lung Cancer. Chest, 2005, 127, 748-754.	0.4	62

#	Article	IF	CITATIONS
113	Association of Regular Aspirin Use and Breast Cancer Risk. Oncology, 2005, 68, 40-47.	0.9	67
114	Increased PGE <sub>2</sub> Levels in Nonmalignant Mucosa Adjacent to Squamous Cell Carcinoma of the Head and Neck. Orl, 2005, 67, 96-100.	0.6	10
115	Cyclooxygenase-2 expression associated with severity of PanIN lesions: A possible link between chronic pancreatitis and pancreatic cancer. Pancreatology, 2005, 5, 361-369.	0.5	44
116	Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochemical and Biophysical Research Communications, 2005, 332, 800-807.	1.0	23
117	Diclofenac attenuates Wnt/β-catenin signaling in colon cancer cells by activation of NF-βB. FEBS Letters, 2005, 579, 4213-4218.	1.3	55
118	American Gastroenterological Association Technical Review on the Role of the Gastroenterologist in the Management of Esophageal Carcinoma. Gastroenterology, 2005, 128, 1471-1505.	0.6	78
119	Cytokines, NF- $\hat{l}^{\circ}$ B, Microenvironment, Intestinal Inflammation and Cancer. Cancer Treatment and Research, 2006, 130, 67-87.	0.2	104
120	A Large Cohort Study of Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs and Prostate Cancer Incidence. Journal of Urology, 2006, 175, 388-388.	0.2	1
121	Chemoprevention of pancreatic cancer: A review of the molecular pathways involved, and evidence for the potential for chemoprevention. Pancreatology, 2006, 6, 429-439.	0.5	27
122	Endometriosis as a model for inflammation–hormone interactions in ovarian and breast cancers. European Journal of Cancer, 2006, 42, 691-703.	1.3	52
123	Inflammation and Cancer. Cancer Treatment and Research, 2006, , 1-38.	0.2	58
124	Chemoprevention of gastric cancer. European Journal of Gastroenterology and Hepatology, 2006, 18, 867-871.	0.8	28
125	Use of Analgesics and Nonsteroidal Anti-inflammatory Drugs, Genetic Predisposition, and Bladder Cancer Risk in Spain. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1696-1702.	1.1	42
126	Sodium salicylate inhibits TNF-α-induced NF-κB activation, cell migration, invasion and ICAM-1 expression in human melanoma cells. Melanoma Research, 2006, 16, 11-22.	0.6	27
127	GROWTH INHIBITION OF MESENCHYMAL STEM CELLS BY ASPIRIN: INVOLVEMENT OF THE WNT/β ATENIN SIGNAL PATHWAY. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 696-701.	0.9	40
128	Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs. Chinese Journal of Digestive Diseases, 2006, 7, 1-6.	1.1	10
129	Colonic mucosal lesions associated with long-term administration of non-steroidal anti-inflammatory drugs. Alimentary Pharmacology and Therapeutics Symposium Series, 2006, 2, 88-95.	0.7	1
130	Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Modern Pathology, 2006, 19, 564-572.	2.9	95

#	Article	IF	CITATIONS
131	Epidemiology and risk factors for pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 197-209.	1.0	489
132	Regular Use of Aspirin and Prostate Cancer Risk (United States). Cancer Causes and Control, 2006, 17, 251-256.	0.8	31
133	Cyclooxygenase-2 Expression Correlates With Membrane-Type-1 Matrix Metalloproteinase Expression in Colorectal Cancer Tissue. Diseases of the Colon and Rectum, 2006, 49, 1184-1192.	0.7	4
134	The role of COX-2 in chemoprevention of colorectal cancer: A friend or an enemy?. Current Colorectal Cancer Reports, 2006, 2, 5-12.	1.0	1
135	Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. Prostaglandins and Other Lipid Mediators, 2006, 81, 150-161.	1.0	26
136	Cancer risk among patients with multiple sclerosis: A population-based register study. International Journal of Cancer, 2006, 118, 979-984.	2.3	123
137	Id-1gene downregulation by sulindac sulfide and its upregulation during tumor development in gastric cancer. International Journal of Cancer, 2006, 118, 1356-1363.	2.3	16
138	Regular aspirin use and esophageal cancer risk. International Journal of Cancer, 2006, 119, 202-207.	2.3	32
139	Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-Metaplasia-Adenocarcinoma Sequence. Cancer Research, 2006, 66, 4975-4982.	0.4	110
140	Perspectives on Pulmonary Inflammation and Lung Cancer Risk in Cigarette Smokers. Inhalation Toxicology, 2006, 18, 667-677.	0.8	97
141	Nitric Oxide–Donating Aspirin Prevents Pancreatic Cancer in a Hamster Tumor Model. Cancer Research, 2006, 66, 4503-4511.	0.4	80
142	Low-Dose Aspirin Affects the Clinicopathological Features of Gastric Cancer. Digestion, 2006, 73, 54-59.	1.2	3
143	Aspirin and Nonsteroidal Anti-inflammatory Drug Use and Risk of Pancreatic Cancer: A Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2561-2564.	1.1	52
144	Association between Nonsteroidal Anti-inflammatory Drug Use and the Incidence of Lung Cancer in the Iowa Women's Health Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2226-2231.	1.1	36
145	Nonsteroidal Anti-inflammatory Drugs and Subsite-Specific Colorectal Cancer Incidence in the Iowa Women's Health Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1785-1790.	1.1	60
146	COX-2 CA-Haplotype Is a Risk Factor for the Development of Esophageal Adenocarcinoma. American Journal of Gastroenterology, 2007, 102, 2373-2379.	0.2	42
147	Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer. New England Journal of Medicine, 2007, 357, 360-369.	13.9	124
148	A Day in the Life of Oscar the Cat. New England Journal of Medicine, 2007, 357, 328-329.	13.9	40

#	ARTICLE	IF	Citations
149	Chemopreventive Effects of Nonsteroidal Anti-Inflammatory Drugs in the Membrane Lipid Composition and Fluidity Parameters of the 1,2-Dimethylhydrazine-Induced Colon Carcinogenesis in Rats. Drug and Chemical Toxicology, 2007, 30, 293-309.	1.2	14
150	The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue. Carcinogenesis, 2007, 29, 120-128.	1.3	8
151	State of the Art Reviews: Health Benefits Related to Exercise in Patients With Chronic Low-Grade Systemic Inflammation. American Journal of Lifestyle Medicine, 2007, 1, 289-298.	0.8	9
152	Nonsteroidal Anti-Inflammatory Drugs and Lung Cancer Risk: A Population-Based Case Control Study. Journal of Thoracic Oncology, 2007, 2, 109-114.	0.5	22
153	Polyamine metabolism and cancer prevention. Biochemical Society Transactions, 2007, 35, 364-368.	1.6	13
154	Statins Reduce the Risk of Pancreatic Cancer in Humans. Pancreas, 2007, 34, 260-265.	0.5	99
155	Cyclooxygenase-2 (COX-2) and the Inflammogenesis of Cancer. Sub-Cellular Biochemistry, 2007, 42, 93-126.	1.0	152
156	Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet, The, 2007, 369, 1603-1613.	6.3	741
157	Aspirin inhibits the proliferation of tobacco-related esophageal squamous carcinomas cell lines through cyclooxygenase 2 pathway. Chinese Medical Journal, 2007, 120, 2086-2091.	0.9	8
158	Sulindac Prevents Esophageal Adenocarcinomas Induced by Gastroduodenal Reflux in Rats. Yonsei Medical Journal, 2007, 48, 1020.	0.9	5
159	Nonsteroidal anti-inflammatory drugs and risk of lung cancer. International Journal of Cancer, 2007, 120, 1565-1572.	2.3	53
160	Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. International Journal of Cancer, 2007, 121, 211-215.	2.3	43
161	Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urology, 2007, 7, 13.	0.6	45
162	Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency. British Journal of Cancer, 2007, 97, 1295-1299.	2.9	33
163	Predictors for squamous re-epithelialization of Barrett?s esophagus after endoscopic biopsy. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 901-907.	1.4	12
164	Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer. Histopathology, 2007, 50, 203-209.	1.6	15
165	Colonic mucosal lesions associated with longâ€term administration of nonâ€steroidal antiâ€inflammatory drugs. Alimentary Pharmacology and Therapeutics, 2006, 24, 88-95.	1.9	4
166	Metaâ€analysis: the use of nonâ€steroidal antiâ€inflammatory drugs and pancreatic cancer risk for different exposure categories. Alimentary Pharmacology and Therapeutics, 2007, 26, 1089-1099.	1.9	38

#	ARTICLE	IF	CITATIONS
167	Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. International Journal of Clinical Practice, 2007, 61, 425-430.	0.8	58
168	Epidemiology of urinary bladder cancer: from tumor development to patient's death. World Journal of Urology, 2007, 25, 285-295.	1.2	221
169	The Anti-Cancer Effect of COX-2 Inhibitors on Gastric Cancer Cells. Digestive Diseases and Sciences, 2007, 52, 1713-1721.	1.1	40
170	NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Research and Treatment, 2007, 101, 191-197.	1.1	75
172	Expression of nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) inversely correlates with tumor progression in gastric adenomas and carcinomas. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1029-1035.	1.2	10
173	Aspirin use and breast cancer risk: a metaâ€analysis and metaâ€regression of observational studies from 2001 to 2005. Pharmacoepidemiology and Drug Safety, 2008, 17, 115-124.	0.9	48
174	Lung cancer and regular use of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Pharmacoepidemiology and Drug Safety, 2008, 17, 322-327.	0.9	25
175	Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma. Pathology Research and Practice, 2008, 204, 527-536.	1.0	32
176	NSAIDs and breast cancer: a possible prevention and treatment strategy. International Journal of Clinical Practice, 2008, 62, 444-449.	0.8	99
177	The COX-2 promoter polymorphism –765 G>C is associated with early-onset, conventional and stump gastric cancers. Modern Pathology, 2008, 21, 685-690.	2.9	36
178	Use of NSAIDs, smoking and lung cancer risk. British Journal of Cancer, 2008, 98, 232-237.	2.9	37
179	Aspirin Dose and Duration of Use and Risk of Colorectal Cancer in Men. Gastroenterology, 2008, 134, 21-28.	0.6	224
180	Natural products as inhibitors of carcinogenesis. Expert Opinion on Investigational Drugs, 2008, 17, 1341-1352.	1.9	52
181	The Arachidonic Acid Pathway and its Role in Prostate Cancer Development and Progression. Journal of Urology, 2008, 179, 1668-1675.	0.2	46
182	Breast Cancer and Use of Nonsteroidal Anti-inflammatory Drugs: A Meta-analysis. Journal of the National Cancer Institute, 2008, 100, 1439-1447.	3.0	193
183	Regular Adult Aspirin Use Decreases the Risk of Non-Small Cell Lung Cancer among Women. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 148-157.	1.1	52
184	Nonsteroidal Anti-inflammatory Drugs and Risk of Esophageal and Gastric Adenocarcinomas in Los Angeles County. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 126-134.	1.1	52
185	Use of Nonsteroidal Antiinflammatory Drugs and Distal Large Bowel Cancer in Whites and African Americans. American Journal of Epidemiology, 2008, 168, 1292-1300.	1.6	11

#	Article	IF	CITATIONS
186	Nonsteroidal Anti-inflammatory Drugs and Change in Mammographic Density: A Cohort Study Using Pharmacy Records on Over 29,000 Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1088-1095.	1.1	16
187	Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1169-1178.	1.1	77
188	Cyclooxygenase-2 as a Target for Cancer Prevention and Treatment. , 2008, , 509-541.		0
189	Nonsteroidal Anti-inflammatory Drug Use and Serum Total Estradiol in Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 680-687.	1.1	50
190	Roles of eicosanoids in prostate cancer. Future Lipidology, 2008, 3, 453-467.	0.5	14
191	What is the future for NSAIDS in preventing breast cancer in older women?. Aging Health, 2008, 4, 207-212.	0.3	0
192	Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. European Journal of Cancer Prevention, 2008, 17, 88-96.	0.6	55
193	Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. British Journal of Cancer, 2009, 100, 551-557.	2.9	160
194	The antecedents of biliary cancer: a primary care case–control study in the United Kingdom. British Journal of Cancer, 2009, 100, 178-180.	2.9	78
195	Nature meets nurture: molecular genetics of gastric cancer. Human Genetics, 2009, 126, 615-628.	1.8	188
196	Long-term use of nonsteroidal anti-inflammatory drugs normalizes the kinetics of gastric epithelial cells in patients with Helicobacter pylori infection via attenuation of gastric mucosal inflammation. Journal of Gastroenterology, 2009, 44, 8-17.	2.3	7
197	Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology, 2009, 17, 55-67.	1.9	294
198	Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2009, 117, 141-150.	1.1	83
199	NSAID use and risk of leukaemia: a populationâ€based caseâ€control study. Pharmacoepidemiology and Drug Safety, 2009, 18, 833-836.	0.9	7
200	Chronic nonsteroidal antiâ€inflammatory drug (NSAID) use suppresses multiple CpG islands hyper methylation (CIHM) of tumor suppressor genes in the human gastric mucosa. Cancer Science, 2009, 100, 1192-1197.	1.7	20
201	Antiâ€gastric cancer effects of celecoxib, a selective COXâ€2 inhibitor, through inhibition of Akt signaling. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 480-487.	1.4	38
202	Effects of cyclooxygenase-2 non-selective and selective inhibitors on proliferation inhibition and apoptosis induction of esophageal squamous carcinoma cells. Ecological Management and Restoration, 2009, 22, 21-31.	0.2	21
203	The effect of aspirin in the recurrence of colorectal adenomas: a metaâ€analysis of randomized controlled trials. Colorectal Disease, 2009, 11, 893-901.	0.7	29

#	Article	IF	CITATIONS
204	Drug-related damage of the ageing gastrointestinal tract. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2009, 23, 849-860.	1.0	17
205	A Preliminary Study on the Postoperative Survival of Patients Given Aspirin After Resection for Squamous Cell Carcinoma of the Esophagus or Adenocarcinoma of the Cardia. Annals of Surgical Oncology, 2009, 16, 1397-1402.	0.7	44
206	Nonsteroidal Antiinflammatory Drugs and Cyclooxygenase Inhibition in the Gastrointestinal Tract: A Trip From Peptic Ulcer to Colon Cancer. American Journal of the Medical Sciences, 2009, 338, 96-106.	0.4	84
207	Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 19, 57-61.	2.5	84
208	Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. European Journal of Cancer Prevention, 2010, 19, 288-298.	0.6	71
211	Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology, 2010, 278, 229-241.	2.0	144
213	Chronic Aspirin Use Suppresses CDH1 Methylation in Human Gastric Mucosa. Digestive Diseases and Sciences, 2010, 55, 54-59.	1.1	29
214	Mouse models of gastric tumors: Wnt activation and PGE2 induction. Pathology International, 2010, 60, 599-607.	0.6	23
215	Hit Identification and Biological Evaluation of Anticancer Pyrazolopyrimidines Endowed with Antiâ€inflammatory Activity. ChemMedChem, 2010, 5, 1242-1246.	1.6	25
216	Use of nonsteroidal antiâ€inflammatory drugs and prostate cancer risk: A metaâ€analysis. International Journal of Cancer, 2010, 127, 1680-1691.	2.3	95
217	Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma. Alimentary Pharmacology and Therapeutics, 2010, 31, 440-451.	1.9	32
218	Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case–control study. British Journal of Cancer, 2010, 102, 1415-1421.	2.9	39
219	Use of Aspirin and Other Nonsteroidal Antiinflammatory Medications in Relation to Prostate Cancer Risk. American Journal of Epidemiology, 2010, 172, 578-590.	1.6	86
220	Inflammation, tumor necrosis factor and Wnt promotion in gastric cancer development. Future Oncology, 2010, 6, 515-526.	1.1	41
221	IKK- and NF-κB-Mediated Functions in Carcinogenesis. Current Topics in Microbiology and Immunology, 2010, 349, 159-169.	0.7	37
222	Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer. Pharmaceuticals, 2010, 3, 3127-3142.	1.7	3
223	Critical Overview on the Benefits and Harms of Aspirin. Pharmaceuticals, 2010, 3, 1491-1506.	1.7	15
224	Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Research, 2010, 12, R15.	2.2	27

#	Article	IF	CITATIONS
225	Changes in the gene expression profile of gastric cancer cells in response to ibuprofen: a gene pathway analysis. Pharmacogenomics Journal, 2011, 11, 412-428.	0.9	34
226	Wnt/ $\hat{l}^2$ -Catenin Signaling Enhances Cyclooxygenase-2 (COX2) Transcriptional Activity in Gastric Cancer Cells. PLoS ONE, 2011, 6, e18562.	1.1	97
227	Meta-analysis: non-steroidal anti-inflammatory drug use and the risk of esophageal squamous cell carcinoma. Ecological Management and Restoration, 2011, 24, 544-549.	0.2	31
228	Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast, 2011, 20, 66-70.	0.9	47
229	Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Research and Treatment, 2011, 126, 149-155.	1.1	82
230	Cyclooxygenase-2 and Gastric Cancer. Cancer and Metastasis Reviews, 2011, 30, 387-395.	2.7	53
231	Prevention by Aspirin of Colorectal Adenoma Recurrence: Some Advances and Latest Results of the APACC Trial. Current Colorectal Cancer Reports, 2011, 7, 33-41.	1.0	1
232	Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. Journal of Surgical Oncology, 2011, 104, 504-510.	0.8	221
233	Associations of aspirin, nonsteroidal antiâ€inflammatory drug and paracetamol use with PSAâ€detected prostate cancer: Findings from a large, populationâ€based, case–control study (the ProtecT study). International Journal of Cancer, 2011, 128, 1442-1448.	2.3	41
234	Aspirin use and risk for lung cancer: a meta-analysis. Annals of Oncology, 2011, 22, 2456-2465.	0.6	32
235	Aspirin, Nonsteroidal Anti-inflammatory Drugs, Acetaminophen, and Pancreatic Cancer Risk: a Clinic-Based Caseâ€"Control Study. Cancer Prevention Research, 2011, 4, 1835-1841.	0.7	72
236	Nonsteroidal Antiinflammatory Drugs and Bladder Cancer: A Pooled Analysis. American Journal of Epidemiology, 2011, 173, 721-730.	1.6	74
237	Molecular Link Mechanisms between Inflammation and Cancer. Current Pharmaceutical Design, 2012, 18, 3831-3852.	0.9	344
238	Ibuprofen delivered by poly(lactic-co-glycolic acid) (PLGA) nanoparticles to human gastric cancer cells exerts antiproliferative activity at very low concentrations. International Journal of Nanomedicine, 2012, 7, 5683.	3.3	24
239	Non-synonymous polymorphism (Gln261Arg) of 12-lipoxygenase in colorectal and thyroid cancers. Familial Cancer, 2012, 11, 615-621.	0.9	5
240	Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut, 2012, 61, 255-261.	6.1	81
241	The role of chemoprevention by selective cyclooxygenase-2 inhibitors in colorectal cancer patients - a population-based study. BMC Cancer, 2012, 12, 582.	1.1	17
242	Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer. Lung Cancer, 2012, 77, 246-251.	0.9	31

#	Article	IF	CITATIONS
243	Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Medical Oncology, 2012, 29, 3092-3100.	1.2	187
244	Inhibition of Pancreatic Intraepithelial Neoplasia Progression to Carcinoma by Nitric Oxide-Releasing Aspirin in p48Cre/+-LSL-KrasG12D/+ Mice. Neoplasia, 2012, 14, 778-IN1.	2.3	41
245	Mechanisms of GI Malignancies., 2012,, 2129-2155.		3
246	Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumor Biology, 2012, 33, 749-756.	0.8	101
247	Meta-Analysis on the Association Between Nonsteroidal Anti-Inflammatory Drug Use and Lung Cancer Risk. Clinical Lung Cancer, 2012, 13, 44-51.	1.1	43
248	COX-derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 49-63.	3.3	33
249	Cyclooxygenaseâ€⊋ expression and clinical parameters in laryngeal squamous cell carcinoma, vocal fold nodule, and laryngeal atypical hyperplasia. Head and Neck, 2013, 35, 52-56.	0.9	6
250	Breast Cancer Prevention by Antihormones and Other Drugs. Hematology/Oncology Clinics of North America, 2013, 27, 657-672.	0.9	16
251	Nonsteroidal antiâ€inflammatory drugs and risk of ovarian cancer: systematic review and metaâ€analysis of observational studies. Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 245-255.	1.3	45
252	A short peptide derived from the gN helix domain of FGF8b suppresses the growth of human prostate cancer cells. Cancer Letters, 2013, 339, 226-236.	3.2	6
253	Inhibitory effects of acetylsalicylic acid on exocrine pancreatic carcinogenesis. Biotechnic and Histochemistry, 2013, 88, 132-137.	0.7	1
254	Inflammation and prostate carcinogenesis. International Journal of Urology, 2013, 20, 150-160.	0.5	86
255	Long-term NSAID use and incident urothelial cell carcinoma in the VITamins and Lifestyle (VITAL) study. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1689-1695.	0.8	11
256	Mechanisms of Gastrointestinal Carcinogenesis. Molecular Pathology Library, 2013, , 3-29.	0.1	0
257	A novel copper(II) mononuclear complex with the non-steroidal anti-inflammatory drug diclofenac: Structural characterization and biological activity. Journal of Inorganic Biochemistry, 2013, 120, 39-43.	1.5	45
258	Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. European Journal of Cancer, 2013, 49, 938-945.	1.3	65
259	Prognostic Significance of COX-2 Expression and Correlation With Bcl-2 and VEGF Expression, Microvessel Density, and Clinical Variables in Classical Hodgkin Lymphoma. American Journal of Surgical Pathology, 2013, 37, 1242-1251.	2.1	34
260	COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs. Frontiers in Oncology, 2013, 3, 181.	1.3	101

#	Article	IF	CITATIONS
261	Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Canadian Urological Association Journal, 2013, 3, 323.	0.3	44
262	Nonsteroidal Anti-Inflammatory Drugs and Prostatic Diseases. BioMed Research International, 2014, 2014, 1-6.	0.9	29
263	Chronic inflammation of the prostate type IV with respect to risk of prostate cancer. Archivio Italiano Di Urologia Andrologia, 2014, 86, 208.	0.4	15
264	Cyclooxygenase-2 and the inflammogenesis of breast cancer. World Journal of Clinical Oncology, 2014, 5, 677.	0.9	143
266	Impact of a complex nutraceutical supplement on primary tumour formation and metastasis in Trp53+/ $\hat{a}$ e" cancer-prone mice. Mutagenesis, 2014, 29, 177-187.	1.0	3
267	Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk. World Journal of Surgical Oncology, 2014, 12, 304.	0.8	23
268	Toad Glandular Secretions and Skin Extractions as Anti-Inflammatory and Anticancer Agents. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-9.	0.5	47
269	Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. British Journal of Cancer, 2014, 111, 1421-1431.	2.9	26
270	The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. Urology, 2014, 84, 1073-1080.	0.5	2
271	Case–Control Study of Aspirin Use and Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1254-1263.	1.1	61
272	Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Medicine, 2014, 12, 55.	2.3	89
273	Clinical evidence of the relationship between aspirin and breast cancer risk (Review). Oncology Reports, 2014, 32, 451-461.	1.2	16
274	Aspirin might reduce the incidence of pancreatic cancer: A meta-analysis of observational studies. Scientific Reports, 2015, 5, 15460.	1.6	37
275	Apoptosis induction by combination of drugs or a conjugated molecule associating non-steroidal anti-inflammatory and nitric oxide donor effects in medullary thyroid cancer models: implication of the tumor suppressor p73. Thyroid Research, 2015, 8, 13.	0.7	4
276	Preparation and Characterization of Colon-Specific Microspheres of Diclofenac for Colorectal Cancer. Tropical Journal of Pharmaceutical Research, 2015, 14, 1541-1547.	0.2	12
277	Neuroendocrine Cell Carcinoma of Unknown Primary Arising in Long Standing History of Multiple Sclerosis. Case Reports in Oncological Medicine, 2015, 2015, 1-4.	0.2	1
278	Chronic Pancreatitis as an Inductor of Pancreatic Cancer $\hat{a} \in \text{``Correlations With Inflammatory Pathways.'}, 0, , .$		0
279	Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer. Translational Oncology, 2015, 8, 339-345.	1.7	174

#	Article	IF	CITATIONS
280	Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis. Breast Cancer Research and Treatment, 2015, 149, 525-536.	1.1	59
281	Targeting the 5′-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer. Expert Opinion on Therapeutic Targets, 2015, 19, 617-632.	1.5	24
282	Prostate Volume Index and Chronic Inflammation of the Prostate Type IV with Respect to the Risk of Prostate Cancer. Urologia Internationalis, 2015, 94, 270-285.	0.6	36
283	Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study. Clinical Cancer Research, 2015, 21, 756-762.	3.2	91
284	Luteolin supplementation adjacent to aspirin treatment reduced dimethylhydrazine-induced experimental colon carcinogenesis in rats. Tumor Biology, 2015, 36, 1179-1190.	0.8	26
285	The C-reactive Protein/Albumin Ratio Is an independent Prognostic Factor for Overall Survival in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy. Journal of Cancer, 2016, 7, 2005-2011.	1.2	23
286	The Effects of Anti-inflammatory Drug Treatment in Gastric Cancer Prevention: an Update of a Meta-analysis. Journal of Cancer, 2016, 7, 2247-2257.	1.2	26
287	APOPTOSIS-INDUCING POTENTIAL OF LAWSONIA ALBA LAM. LEAVES ON HEPATOCELLULAR CARCINOMA (HEP-G2) CELLS ALONG WITH ITS ANTI-OXIDANT PROPERTY. International Journal of Pharmacy and Pharmaceutical Sciences, 2016, 8, 156.	0.3	1
288	Long-Term Low-Dose Aspirin Use Reduces Gastric Cancer Incidence: A Nationwide Cohort Study. Cancer Research and Treatment, 2016, 48, 798-805.	1.3	33
289	Molecular alterations in gastric cancer with special reference to the early-onset subtype. World Journal of Gastroenterology, 2016, 22, 2460.	1.4	52
290	Protective Effects of <i>Pinus halepensis</i> L. Essential Oil on Aspirin-induced Acute Liver and Kidney Damage in Female Wistar Albino Rats. Journal of Oleo Science, 2016, 65, 701-712.	0.6	12
291	Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study. Cancer Causes and Control, 2016, 27, 1067-1079.	0.8	24
292	The Neutrophil-to-Lymphocyte Ratio as a Marker of Lymph Node Status in Patients with Rectal Cancer. Oncology, 2016, 91, 69-77.	0.9	15
293	Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study. BMC Cancer, 2016, 16, 660.	1.1	26
294	The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives. Breast Care, 2016, 11, 339-344.	0.8	42
295	Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer. Medicine (United) Tj ETQq $1\ 1$	0.784314 0.4	rgBT/Overlo
296	Chronic Inflammation in Prostate Biopsy Cores is an Independent Factor that Lowers the Risk of Prostate Cancer Detection and is Inversely Associated with the Number of Positive Cores in Patients Elected to a First Biopsy. Current Urology, 2016, 9, 82-92.	0.4	9
297	The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 484.e1-484.e8.	0.8	66

#	Article	IF	CITATIONS
298	Meta-analysis of aspirin use and risk of lung cancer shows notable results. European Journal of Cancer Prevention, 2016, 25, 259-268.	0.6	30
299	Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. Mayo Clinic Proceedings, 2016, 91, 71-80.	1.4	20
300	The role of prostatic inflammation in the development and progression of benign and malignant diseases. Current Opinion in Urology, 2017, 27, 99-106.	0.9	54
301	Aspirin Use and Reduced Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 68-74.	1.1	58
302	Protective effects of essential oil of <i>Citrus limon</i> against aspirin-induced toxicity in IEC-6 cells. Applied Physiology, Nutrition and Metabolism, 2017, 42, 479-486.	0.9	9
303	Pancreatic cancer screening: Still a delusion?. Pancreatology, 2017, 17, 754-765.	0.5	20
304	Potential protective effects of alpha-pinene against cytotoxicity caused by aspirin in the IEC-6 cells. Biomedicine and Pharmacotherapy, 2017, 93, 961-968.	2.5	55
305	Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS. Scientific Reports, 2017, 7, 17166.	1.6	57
306	Clinical impact of preoperative albumin to globulin ratio in gastric cancer patients with curative intent. American Journal of Surgery, 2017, 213, 120-126.	0.9	50
307	Intraprostatic Chronic Inflammation is Associated with a Reduced Risk of Prostate Cancer in Patients Elected to a First Random Biopsy Set. Tumori, 2017, 103, 475-482.	0.6	10
308	Prognostic value of the C-reactive protein/albumin ratio in patients with laryngeal squamous cell carcinoma. OncoTargets and Therapy, 2017, Volume 10, 879-884.	1.0	24
309	Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology, 2018, 154, 1380-1390.e5.	0.6	38
310	The protective effects of $18\hat{l}^2$ -glycyrrhetinic acid against inflammation microenvironment in gastric tumorigenesis targeting PGE2-EP2 receptor-mediated arachidonic acid pathway. European Journal of Inflammation, 2018, 16, 205873921876299.	0.2	5
311	Intake of Non-steroidal Anti-inflammatory Drugs and the Risk of Prostate Cancer: A Meta-Analysis. Frontiers in Oncology, 2018, 8, 437.	1.3	17
312	Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma. Drug Development Research, 2019, 80, 556-565.	1.4	19
313	Aspirin and nonsteroidal antiâ€inflammatory drug use and keratinocyte cancers: a large populationâ€based cohort study of skin cancer in Australia. British Journal of Dermatology, 2019, 181, 749-760.	1.4	21
314	Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention. British Journal of Cancer, 2019, 120, 407-423.	2.9	28
315	Preoperative C-reactive protein/albumin ratio to predict mortality and recurrence of patients with hepatocellular carcinoma after curative resection. Medicina ClÃnica (English Edition), 2019, 153, 183-190.	0.1	2

#	Article	IF	Citations
316	Prognostic significance of CD163 expression and its correlation with cyclooxygenase-2 and vascular endothelial growth factor expression in cutaneous melanoma. Melanoma Research, 2019, 29, 501-509.	0.6	12
317	Preoperative C-reactive protein/albumin ratio to predict mortality and recurrence of patients with hepatocellular carcinoma after curative resection. Medicina ClÃnica, 2019, 153, 183-190.	0.3	14
318	Nonneoplastic Diseases of the Prostate. , 2020, , 358-414.e13.		0
319	Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau). World Journal of Urology, 2020, 38, 2485-2491.	1.2	5
320	Effect of aspirin use on gastric cancer incidence and survival: A systematic review and metaâ€analysis. JGH Open, 2020, 4, 117-125.	0.7	18
321	The Epidemiology of Pancreatic Cancer and the Association With Acetylsalicylic Acid in the United States. Pancreas, 2020, 49, 1207-1212.	0.5	8
322	The C-reactive protein to albumin ratio predicts postoperative complication in patients who undergo gastrectomy for gastric cancer. Heliyon, 2020, 6, e04220.	1.4	8
323	"Dual-Key-and-Lock―dual drug carrier for dual mode imaging guided chemo-photothermal therapy. Biomaterials Science, 2020, 8, 6212-6224.	2.6	6
324	Prussian Blue modified Metal Organic Frameworks for imaging guided synergetic tumor therapy with hypoxia modulation. Journal of Alloys and Compounds, 2021, 853, 157329.	2.8	22
325	Prevention Strategies for Esophageal Cancer—An Expert Review. Cancers, 2021, 13, 2183.	1.7	19
326	Updated perspective and directions on hereditary diffuse gastric cancer., 2021,, 217-258.		1
328	Genetic Instability and Chronic Inflammation in Gastrointestinal Cancers., 2010,, 351-397.		1
329	Cyclooxygenase-2 and Chronic Inflammation: Drivers of Colorectal Tumorigenesis., 2012, , 157-182.		1
330	COX-2 in cancer. , 2004, , 227-243.		3
331	Relevance of Network Hierarchy in Cancer Drug-Target Selection., 2012,, 339-362.		3
332	Cancer of the Pancreas. , 2006, , 721-762.		80
333	Risks of solid cancers in elderly persons with osteoarthritis or ankylosing spondylitis. Rheumatology, 2020, 59, 3817-3825.	0.9	13
334	Avoidance of ingestion of anti-inflammatory drugs in dyspepsia is confounding variable. BMJ: British Medical Journal, 2001, 322, 46-46.	2.4	19

#	Article	IF	CITATIONS
335	Cyclooxygenase as a Target in Lung Cancer. Clinical Cancer Research, 2004, 10, 4266s-4269s.	3.2	140
336	Inflammation and de-differentiation in pancreatic carcinogenesis. World Journal of Clinical Cases, 2018, 6, 882-891.	0.3	3
338	Use of Nonsteroidal Anti-Inflammatory Drugs and Bladder Cancer Risk: A Meta-Analysis of Epidemiologic Studies. PLoS ONE, 2013, 8, e70008.	1.1	18
339	The Pretreatment Albumin to Globulin Ratio Has Predictive Value for Long-Term Mortality in Nasopharyngeal Carcinoma. PLoS ONE, 2014, 9, e94473.	1.1	99
340	Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis. Oncotarget, 2017, 8, 4781-4795.	0.8	59
341	Nonsteroidal Anti-Inflammatory Drugs Induce Asymptomatic Gastroduodenal Ulcers in the Japanese Population: A Case-Control Study on Its Prevalence and the Protective Effect of Anti-Ulcer Agents. Journal of Clinical Biochemistry and Nutrition, 2006, 39, 145-152.	0.6	3
342	Potential use of routine databases in health technology assessment. Health Technology Assessment, 2005, 9, 1-92, iii-iv.	1.3	68
343	Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: Implications on chemoprevention. World Journal of Gastroenterology, 2005, 11, 41.	1.4	20
344	Early-onset gastric cancer: Learning lessons from the young. World Journal of Gastrointestinal Oncology, 2010, 2, 59.	0.8	32
345	New Prognostic Scoring System for Incurable Stage IV Colorectal Cancer. Asian Pacific Journal of Cancer Prevention, 2016, 17, 597-601.	0.5	8
347	Interplay between inflammation and tumor angiogenesis., 2004,, 99-121.		0
348	Mechanisms of Gastrointestinal Malignancies. , 2006, , 477-498.		0
350	The Role of Drugs and Nutrition in the Prevention of Esophageal Adenocarcinoma Associated with Barrett's Esophagus., 2007,, 17-31.		0
351	Prostaglandin and Transforming Growth Factor $\hat{I}^2$ Signaling in Gastric Cancer. , 2009, , 513-540.		0
353	Epidemiology of Lung Cancer in Women. , 2013, , 1191-1208.		0
354	Epidemiology of Barrett Esophagus and Risk Factors for Progression. , 2019, , 323-338.		1
355	Can aspirin use reduce the risk of pancreatic cancer: an updated systematic review and meta-analysis. Journal of Pancreatology, 2020, 3, 201-210.	0.3	3
356	Barrett's Esophagus. , 2005, , 346-373.		0

#	Article	IF	CITATIONS
357	Barrett's Esophagus. , 2005, , 325-342.		0
359	Avoidance of ingestion of anti-inflammatory drugs in dyspepsia is confounding variable. BMJ: British Medical Journal, 2001, 322, 46.	2.4	0
362	Effect of aspirin administration on body weight and liver enzymes in male rats. Annals of Medical Physiology, 2021, 5, 13-16.	0.2	0
363	Development and Validation of a New Integrative Score Based on Various Systemic Inflammatory and Nutritional Indicators in Predicting Prognosis in Patients With Resectable Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study. Cancer Control, 2022, 29, 107327482210913.	0.7	0
365	Barrett's Esophagus., 0,, 55-68.		0
368	The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Molecular Cancer Therapeutics, 2004, 3, 299-307.	1.9	110
369	Inverse Association between Nonsteroidal Anti-inflammatory Drugs and Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 649-653.	1.1	57
370	Aspirin and Other Nonsteroidal Anti-inflammatory Drugs and Breast Cancer Incidence in a Large U.S. Cohort. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 261-264.	1.1	49